Alphamab Oncology Balance Sheet Health
Financial Health criteria checks 5/6
Alphamab Oncology has a total shareholder equity of CN¥1.8B and total debt of CN¥182.2M, which brings its debt-to-equity ratio to 9.9%. Its total assets and total liabilities are CN¥2.2B and CN¥409.9M respectively. Alphamab Oncology's EBIT is CN¥101.0M making its interest coverage ratio -2.6. It has cash and short-term investments of CN¥1.6B.
Key information
9.95%
Debt to equity ratio
CN¥182.25m
Debt
| Interest coverage ratio | -2.6x |
| Cash | CN¥1.57b |
| Equity | CN¥1.83b |
| Total liabilities | CN¥409.87m |
| Total assets | CN¥2.24b |
Recent financial health updates
Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?
Oct 04
Is Alphamab Oncology (HKG:9966) A Risky Investment?
May 21Recent updates
Revenues Not Telling The Story For Alphamab Oncology (HKG:9966) After Shares Rise 26%
Apr 15Market Participants Recognise Alphamab Oncology's (HKG:9966) Revenues Pushing Shares 88% Higher
Feb 28After Leaping 31% Alphamab Oncology (HKG:9966) Shares Are Not Flying Under The Radar
Nov 14Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable
Sep 30Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding
Jun 20Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up
May 06Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking
Mar 13Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price
Jan 17Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch
May 21Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts
Mar 01Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?
Oct 04Is Alphamab Oncology (HKG:9966) A Risky Investment?
May 21Financial Position Analysis
Short Term Liabilities: 9966's short term assets (CN¥1.7B) exceed its short term liabilities (CN¥254.0M).
Long Term Liabilities: 9966's short term assets (CN¥1.7B) exceed its long term liabilities (CN¥155.8M).
Debt to Equity History and Analysis
Debt Level: 9966 has more cash than its total debt.
Reducing Debt: 9966's debt to equity ratio has increased from 9.5% to 9.9% over the past 5 years.
Debt Coverage: 9966's debt is well covered by operating cash flow (116.5%).
Interest Coverage: 9966 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/28 09:23 |
| End of Day Share Price | 2025/05/28 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alphamab Oncology is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wangbin Zhou | Citigroup Inc |
| null null | CLSA |
| null null | Guoyuan Securities (HK) Ltd |